hotspot -WSS

hotspot

author：explore 2025-08-24 19:11:09 - browse：89

Andrew Witty, Chief Executive Officer of UnitedHealth Group, testifies at a Senate Finance Committee hearing examining cyber attacks.-- health tech coverage from STAT — UnitedHealth Group CEO Andrew Witty said the company was beginning to see a “disturbance” in its Medicaid medical costs. Jacquelyn Martin/AP

You’re reading the web version of Health Care Inc., STAT’s weekly newsletterfollowing the flow of money in medicine. Sign upto get it in your inbox every Monday.

What’s next for Risant?

Kaiser Permanente grabbed everyone’s attention last year when it said it was creating Risant Health, a new and vague entity that acquired Geisinger and had plans to scoop up at least four more health systems that are focused on “value-based care.”

Well, nothing has happened since then, at least publicly. Instead, everyone has been playing the parlor game of guessing who those next systems could be. There are some rumblings that the next deal could be announced in the near future. After reading some recent hospital financial reports, it’s clear there are a handful of systems that mirror Geisinger’s shaky trajectory and could find themselves in Kaiser’s crosshairs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Antibiotic resistance nearly killed me, so I'm raising awareness of it

WSS

Making the case for fair compensation in clinical trials

Insmed lung disease drug hits target in key Phase 3 trial

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Making the case for fair compensation in clinical trials

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

First Opinion Podcast: What happens when kids become caregivers?

explore

hotspot

What’s next for Risant?

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

explore

Medical leaders decry Supreme Court decision on affirmative action

Reports of telehealth's death have been greatly exaggerated

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Stigma and the return of syphilis

Drug repurposing or repositioning? The language matters

David Sabatini, ex

Drug repurposing or repositioning? The language matters

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Trump demands the U.S. pay no more for drugs than other countries … again

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

hotspot

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Reports of telehealth's death have been greatly exaggerated

Adam's Biotech Scorecard: Do Sarepta's exon

David Sabatini, ex

Do more moles mean more problems? Not so, says new study

Addressing health care workers' trauma can help fight burnout

focus

entertainment

hotspot

knowledge